0001193125-20-297165.txt : 20201119 0001193125-20-297165.hdr.sgml : 20201119 20201118183954 ACCESSION NUMBER: 0001193125-20-297165 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20201118 ITEM INFORMATION: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201119 DATE AS OF CHANGE: 20201118 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bausch Health Companies Inc. CENTRAL INDEX KEY: 0000885590 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14956 FILM NUMBER: 201326499 BUSINESS ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 BUSINESS PHONE: 514-744-6792 MAIL ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 FORMER COMPANY: FORMER CONFORMED NAME: Valeant Pharmaceuticals International, Inc. DATE OF NAME CHANGE: 20100928 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL Corp DATE OF NAME CHANGE: 20100416 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL DATE OF NAME CHANGE: 19960522 8-K 1 d19559d8k.htm 8-K 8-K
0000885590 false 0000885590 2020-11-18 2020-11-18

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of the earliest event reported): November 18, 2020

(November 18, 2020)

 

 

Bausch Health Companies Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

British Columbia, Canada   001-14956   98-0448205

(State or Other Jurisdiction of

Incorporation or Organization)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification Number)

2150 St. Elzéar Blvd. West

Laval, Quebec

Canada H7L 4A8

(Address of Principal Executive Offices)(Zip Code)

514-744-6792

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Shares, No Par Value   BHC   New York Stock Exchange, Toronto Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 2.04.

Triggering Event That Accelerates or Increases a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement

On November 18, 2020, Bausch Health Companies Inc. (the “Company”) issued conditional notices of redemption to redeem in full its outstanding (i) €1,500.0 million aggregate principal amount of outstanding 4.50% Senior Notes due 2023 (the “Euro Notes”) and (ii) $233.0 million aggregate principal amount of 5.50% Senior Notes due 2023 (the “5.50% Notes” and, together with the Euro Notes, the “Existing Notes”). The redemptions are expected to occur on December 18, 2020 (the “Redemption Date”), subject to satisfaction or waiver by the Company of the Conditions (as defined below). The Euro Notes were issued under an indenture dated as of March 27, 2015, by and among the Company, the guarantors signatory thereto and The Bank of New York Mellon, as trustee, as supplemented and amended (the “March Indenture”) and the 5.50% Notes were issued under an indenture dated as of January 30, 2015, by and among the Company, the guarantors signatory thereto and The Bank of New York Mellon, as trustee, as supplemented and amended (the “January Indenture” and, together with the March Indenture, the “Indentures”). The Existing Notes will be redeemed pursuant to Article 3 of each Indenture if the applicable Conditions are satisfied or waived. The redemption price for the Euro Notes will be €1,000 per €1,000 principal amount and the redemption price for the 5.50% Notes will be $1,000 per $1,000 principal amount, in each case, plus accrued and unpaid interest to, but not including, the Redemption Date.

The redemption of the Euro Notes is conditioned upon the completion by the Company or its subsidiaries of one or more debt financings in an aggregate principal amount of at least $1.75 billion (the “Euro Condition”) and the redemption of the 5.50% Notes is conditioned upon the completion by the Company or its subsidiaries of one or more debt financings in an aggregate principal amount of at least $2.0 billion (the “5.50% Condition” and, together with the Euro Condition, the “Conditions”), each of which the Company expects to satisfy upon closing of the offering of the Notes (as defined below). Any such financings are subject to market and other conditions.

The foregoing is qualified by reference to the press release that is attached as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference.

Item 8.01 Other Events.

Unsecured Notes Offering

On November 18, 2020, the Company announced that it launched, priced and upsized an offering of $1.0 billion aggregate principal amount of 5.000% Senior Notes due 2029 (the “2029 Notes”) and $1.0 billion aggregate principal amount of 5.250% Senior Notes due 2031 (the “2031 Notes” and, together with the 2029 Notes, the “Notes”). The size of the offering reflects an increase of $250 million aggregate from the previously announced offering size of $1.75 billion. The offering price for the 2029 Notes was 100% of the principal amount thereof and the offering price of the 2031 Notes was 100% of the principal amount thereof. The Notes will be offered in the United States to qualified institutional investors pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.

The Company also issued press releases pursuant to Rule 135c under the Securities Act relating to the offering of the Notes. In accordance with Rule 135c(d) under the Securities Act, copies of the press releases are attached hereto as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K, which are incorporated herein by reference.

The foregoing is qualified by reference to the press releases that are attached as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K, which are incorporated herein by reference.

This Current Report on Form 8-K and the press releases attached hereto as Exhibits 99.1 and 99.2 do not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. These securities will not be registered under the Securities Act or any state securities laws and, unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the securities in Canada will be made on a basis which is exempt from the prospectus requirements of such securities laws.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

 

Exhibit
Number

   

Description

  99.1    Press release announcing the launch of the notes offering and the conditional redemption of the Existing Notes, dated November 18, 2020
  99.2    Press release announcing the pricing and upsize of the notes offering and the conditional redemption of additional series of the Existing Notes, dated November 18, 2020
  104    The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

BAUSCH HEALTH COMPANIES INC.

By:

  

/s/ Paul S. Herendeen

Name:

  

Paul S. Herendeen

Title:

  

Executive Vice President, Chief Financial Officer

Date: November 18, 2020

 EX-99.1 2 d19559dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

 

Investor Contact:    Media Contact:
Arthur Shannon    Lainie Keller
arthur.shannon@bauschhealth.com    lainie.keller@bauschhealth.com
(514) 856-3855    (908) 927-1198
(877) 281-6642 (toll free)   

BAUSCH HEALTH ANNOUNCES LAUNCH OF PRIVATE OFFERING OF SENIOR NOTES AND

CONDITIONAL REDEMPTION OF EXISTING SENIOR NOTES

LAVAL, Quebec, Nov. 18, 2020 — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) announced today that it has launched an offering of a combined $1.75 billion aggregate principal amount of new senior notes due 2029 (the “2029 Notes”) and new senior notes due 2031 (the “2031 Notes” and, together with the 2029 Notes, the “Notes”). Bausch Health intends to use the proceeds from the offering of the Notes, along with cash on hand, to fund the conditional redemption (the “Redemption”) in full of its outstanding €1.5 billion aggregate principal amount of 4.50% Senior Notes due 2023 (the “Existing Notes”) and to pay related fees and expenses.

The Notes will be guaranteed by each of the Company’s subsidiaries that are guarantors under the Company’s credit agreement and existing senior notes.

The Notes will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities law and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. The Notes will be offered in the United States only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act. The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the Notes in Canada will be made on a basis, which is exempt from the prospectus requirements of such securities laws.

The Company also announced that it intends to issue a conditional notice of redemption today to redeem the full aggregate principal amount of outstanding Existing Notes. The Redemption will be conditioned upon the completion by the Company or its subsidiaries of one or more debt financings in an aggregate principal amount of at least $1.75 billion (the “Condition”).

A copy of the conditional notice of redemption with respect to the Existing Notes will be issued to the record holders of the Existing Notes. Payment of the redemption price and surrender of the Existing Notes for redemption will be made through the facilities of the Depository Trust Company in accordance with the applicable procedures of the Depository Trust Company on Dec. 18, 2020, unless the Condition is not satisfied, in which case the redemption date will be delayed until the Condition is satisfied. The name and address of the paying agent are as follows: The Bank of New York Mellon Trust Company, N.A., c/o The Bank of New York Mellon; 111 Sanders Creek Parkway, East Syracuse, N.Y. 13057; Attn: Redemption Unit; Tel: (800) 254- 2826.

The foregoing transactions are subject to market and other conditions and are anticipated to close in the fourth quarter of 2020. However, there can be no assurance that the Company will be able to successfully complete the transactions, on the terms described above, or at all.

This news release is being issued pursuant to Rule 135c under the Securities Act and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people’s lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.

Forward-looking Statements

This news release may contain forward-looking statements, including, but not limited to, our financing plans, including the offering of the Notes and the details thereof, including the proposed use of proceeds therefrom and other expected effects of the offering of the Notes. Forward-looking statements may generally be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on the Company, including but not limited to its supply chain, third-party suppliers, project development timelines, employee base, liquidity, stock price, financial condition and costs (which may increase) and revenue and margins (both of which may decrease), other risks related to our business, including risks related to our pending legal and governmental proceedings, legislative and policy efforts, actions by the U.S. Food and Drug Administration and other regulators, our substantial debt, uncertainties associated with acquisitions and product launches, and risks and uncertainties discussed in our most recent annual and quarterly reports and detailed from time to time in our other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which risks and uncertainties are incorporated herein by reference. Management has also made certain assumptions in assessing the anticipated impacts of the COVID-19 pandemic on the Company and its results of operations and financial conditions, including: that there will be no material restrictions on access to health care products and services resulting from a possible resurgence of the virus on a global basis in the fourth quarter of 2020; that the strict social restrictions seen earlier this year will not be materially re-enacted in the event of a material resurgence of the virus; that there will be an ongoing gradual global recovery as the macroeconomic and health care impacts of the COVID-19 pandemic run their course; that the largest impact to the Company’s businesses were seen in the second quarter of 2020 although we expect additional COVID-19 pandemic related declines in the year-over-year revenues in the remainder of 2020 in many of our businesses and geographies; anticipate that our affected businesses could possibly return to pre-pandemic levels as early as late 2020 or in 2021, but that rates of recovery will vary by geography and business unit, with some regions and business units expected to lag in recovery possibly beyond 2021; and no major interruptions in the Company’s supply chain and distribution channels. If any of these assumptions regarding the impacts of the COVID-19 pandemic are incorrect, our actual results could differ materially from those described in these forward-looking statements. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. We undertake no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, except as required by law.

###

 

 

2 | Page

EX-99.2 3 d19559dex992.htm EX-99.2 EX-99.2

Exhibit 99.2

 

LOGO

 

Investor Contact:    Media Contact:
Arthur Shannon    Lainie Keller
arthur.shannon@bauschhealth.com    lainie.keller@bauschhealth.com
(514) 856-3855    (908) 927-1198
(877) 281-6642 (toll free)   

BAUSCH HEALTH ANNOUNCES PRICING AND UPSIZE OF PRIVATE OFFERING OF SENIOR NOTES AND CONDITIONAL REDEMPTION OF ADDITIONAL SERIES OF EXISTING SENIOR NOTES

Following Redemptions, Bausch Health Will Have No Note Maturities Until 2024

LAVAL, Quebec, Nov. 18, 2020 — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) announced today that it has priced and upsized its previously announced offering of $1.0 billion aggregate principal amount of 5.000% senior notes due 2029 (the “2029 Notes”) and $1.0 billion aggregate principal amount of 5.250% senior notes due 2031 (the “2031 Notes” and, together with the 2029 Notes, the “Notes”). The size of the offering reflects an increase of $250 million from the previously announced offering size of $1.75 billion. The 2029 Notes will be sold to investors at a price of 100% of the principal amount thereof, and the 2031 Notes will be sold to investors at a price of 100% of the principal amount thereof.

The proceeds from the offering of the Notes, along with cash on hand, are expected to be used to fund the Company’s (i) previously announced conditional redemption (the “Euro Redemption”) in full of its outstanding €1.5 billion aggregate principal amount of 4.50% Senior Notes due 2023 (the “Euro Notes”) and (ii) conditional redemption (the “5.50% Redemption”) in full of its outstanding $233 million aggregate principal amount of 5.50% Senior Notes due 2023 (the “5.50% Notes” and, together with the Euro Notes, the “Existing Notes”), and to pay related fees and expenses. With these redemptions, Bausch Health will have no note maturities until 2024.

The Notes will be guaranteed by each of the Company’s subsidiaries that are guarantors under the Company’s credit agreement and existing senior notes. Consummation of the offering of the Notes is subject to various closing conditions.

The Notes will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities law and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. The Notes will be offered in the United States only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act. The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the Notes in Canada will be made on a basis, which is exempt from the prospectus requirements of such securities laws.

This announcement does not constitute a notice of redemption with respect to the Existing Notes. The Euro Redemption is conditioned upon the completion by the Company or its subsidiaries of one or more debt financings in an aggregate principal amount of at least $1.75 billion, which the Company expects to satisfy upon closing of the offering of the Notes.

The Company also announced that it has issued today a conditional notice of redemption to redeem the full aggregate principal amount of outstanding 5.50% Notes. The 5.50% Redemption will be conditioned upon the completion by the Company or its subsidiaries of one or more debt financings in an aggregate principal amount of at least $2.0 billion (the “5.50% Condition”), which the Company expects to satisfy upon closing of the offering of the Notes.

A copy of the conditional notice of redemption with respect to the 5.50% Notes has been issued to the record holders of the 5.50% Notes. Payment of the redemption price and surrender of the 5.50% Notes for redemption will be made through the facilities of the Depository Trust Company in accordance with the applicable procedures of the Depository Trust Company on Dec. 18, 2020, unless the 5.50% Condition is not satisfied, in which case the redemption date will be delayed until the 5.50% Condition is satisfied. The name and address of the paying agent are as follows: The Bank of New York Mellon Trust Company, N.A., c/o The Bank of New York Mellon; 111 Sanders Creek Parkway, East Syracuse, N.Y. 13057; Attn: Redemption Unit; Tel: (800) 254- 2826.

This news release is being issued pursuant to Rule 135c under the Securities Act and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people’s lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.

 

2  |   Page     

Forward-looking Statements

This news release may contain forward-looking statements, including, but not limited to, our financing plans, including the offering of the Notes and the details thereof, including the proposed use of proceeds therefrom and other expected effects of the offering of the Notes. Forward-looking statements may generally be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on the Company, including but not limited to its supply chain, third-party suppliers, project development timelines, employee base, liquidity, stock price, financial condition and costs (which may increase) and revenue and margins (both of which may decrease), other risks related to our business, including risks related to our pending legal and governmental proceedings, legislative and policy efforts, actions by the U.S. Food and Drug Administration and other regulators, our substantial debt, uncertainties associated with acquisitions and product launches, and risks and uncertainties discussed in our most recent annual and quarterly reports and detailed from time to time in our other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which risks and uncertainties are incorporated herein by reference. Management has also made certain assumptions in assessing the anticipated impacts of the COVID-19 pandemic on the Company and its results of operations and financial conditions, including: that there will be no material restrictions on access to health care products and services resulting from a possible resurgence of the virus on a global basis in the fourth quarter of 2020; that the strict social restrictions seen earlier this year will not be materially re-enacted in the event of a material resurgence of the virus; that there will be an ongoing gradual global recovery as the macroeconomic and health care impacts of the COVID-19 pandemic run their course; that the largest impact to the Company’s businesses were seen in the second quarter of 2020 although we expect additional COVID-19 pandemic related declines in the year-over-year revenues in the remainder of 2020 in many of our businesses and geographies; anticipate that our affected businesses could possibly return to pre-pandemic levels as early as late 2020 or in 2021, but that rates of recovery will vary by geography and business unit, with some regions and business units expected to lag in recovery possibly beyond 2021; and no major interruptions in the Company’s supply chain and distribution channels. If any of these assumptions regarding the impacts of the COVID-19 pandemic are incorrect, our actual results could differ materially from those described in these forward-looking statements. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. We undertake no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, except as required by law.

###

 

3  |   Page     
 EX-101.SCH 4 bhc-20201118.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 bhc-20201118_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Country Entity Address, Country Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 6 bhc-20201118_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g19559dsp6.jpg GRAPHIC begin 644 g19559dsp6.jpg M_]C_X 02D9)1@ ! $ 8 !@ #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP"$ @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\< M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3H.$A8:' MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7 MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1 (! @0$ P0'!00$ $"=P ! @,1 M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_ !$( "@ ]P,!$0 "$0$#$0'_V@ , M P$ A$#$0 _ /?B0HR3@4 )O7LP_.@!<^E "T -\Q1W'YT *2 ,G@4 ('4G M (S0 %PIP3B@!0P/2@"M)J-E#+Y4MY!')_<:0 _E0!95@P!4Y!Z$4 !8+UX MH @BO[2>0QPW,,CC^%9 3^5 $^<#/2@!-ZYP"#0 %@.IQ0 H8'ITH "V* $# M@G H$FF!8+UH!M+<4-D4KC#.*8!F@ S0 9Q0!!#>V]Q))'#*CO$<.JL"5/O5 M.+2NR%--M+H3;N<5)9')=P0R1QR2*CR'" G!8^U-1;5T0YQBTFR7-3Q'X4#/%7UB M7QDZR3.Z_97.&8GNM,#2^,D\T.IZ6(I70&%\[6(_B%"$0ZOXBU#2OA;X?BM) MWCEO X>4'YL*QXS[Y_2@#'T#P1/XFT=M2&LQ)^'BL;^WNO[.F5E;S 2(R 2"/RQ^- (Q?&OBO4]>\22Z9I\\@M4E\B**(X\P MYQD^N30!3U7P3XC\.:?_ &K*P5$(+-%(2R9Z9_&@#K_!7BJ]UCPIKUC?3-+/ M:VKO'(Q^8J5;K]"!^= S#^$][)_PETOVBY;9]D?[[\9W+ZT"-SXPW9,&D?9; M@_>EW>6_LO7%.,6]D*4E'=G2_#J\C'@73O/N%\W]YG>_/^L;UI/1V&FFKHZT M,' 92"I'!'>D!R_@B5Y+;4C([-MO7 RBJ:G+ M_:-9>\Z3L='9ZI:7VGB^@E!@VEBQXVXZYKBG3E"7(UJ>G3KPJ4_:1>AS[>+[ MN[E?^RM(ENH$./-S@-]*[/J<(_Q9V9YKS&<_X-.Z-+1/$*:L\MO+ ]K>0\O" M_7'J*PK89T5S)W77@ZKI5,1-*]K?J1:=XJO8]:U2X;3;B7SBG[I3_ *K (Y^M:5<% M!TX14TO/N12S"K&K.7(WY=B_XBO4.J^&+V=3 AW2NK=4X4D&L,-"U.K!:G3C M:EJU&3T);GQG>0YFCT6VEE@'KE"&'\C^=#!&;\*KR"S\:+]HD6,2P/& MI8X&<@X_2AB1I?&*\@N-;T^&&57:* E]ISC)X_E0AFA.NA/\,]"T_7+AK:5X MC+;R*N2.?\&% &'9?#K4+^R%_H>JPW-NQ(4@E#D'�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end XML 8 d19559d8k_htm.xml IDEA: XBRL DOCUMENT 0000885590 2020-11-18 2020-11-18 0000885590 false 8-K 2020-11-18 Bausch Health Companies Inc. A1 CA 001-14956 98-0448205 2150 St. Elzéar Blvd. West Laval QC CA H7L 4A8 514 744-6792 false false false false Common Shares, No Par Value BHC NYSE false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information
Nov. 18, 2020
Cover [Abstract]  
Document Type 8-K
Document Period End Date Nov. 18, 2020
Entity Registrant Name Bausch Health Companies Inc.
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One 2150 St. Elzéar Blvd. West
Entity Address, City or Town Laval
Entity Address, Country CA
Entity Address, State or Province QC
Entity Address, Postal Zip Code H7L 4A8
Entity File Number 001-14956
Entity Tax Identification Number 98-0448205
City Area Code 514
Local Phone Number 744-6792
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, No Par Value
Trading Symbol BHC
Security Exchange Name NYSE
Entity Emerging Growth Company false
Entity Central Index Key 0000885590
Amendment Flag false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.bauschhealth.com//20201118/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d19559d8k.htm bhc-20201118.xsd bhc-20201118_lab.xml bhc-20201118_pre.xml d19559dex991.htm d19559dex992.htm http://xbrl.sec.gov/dei/2019-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d19559d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d19559d8k.htm" ] }, "labelLink": { "local": [ "bhc-20201118_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "bhc-20201118_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "bhc-20201118.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bhc", "nsuri": "http://www.bauschhealth.com/20201118", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d19559d8k.htm", "contextRef": "duration_2020-11-18_to_2020-11-18", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.bauschhealth.com//20201118/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d19559d8k.htm", "contextRef": "duration_2020-11-18_to_2020-11-18", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20201118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20201118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20201118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20201118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20201118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20201118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20201118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20201118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20201118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20201118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20201118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20201118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20201118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20201118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20201118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20201118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20201118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20201118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20201118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20201118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20201118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20201118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20201118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-20-297165-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-297165-xbrl.zip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end